Lupus Nephritis market size is projected to grow at a CAGR of 8.5% by 2034

The Lupus Nephritis market size was estimated at USD 1,958 million in 2025 and is expected to expand at a notable CAGR of 8.5% over the forecast period from 2020 to 2034. DelveInsight’s comprehensive market research provides critical insights into such market trends, enabling stakeholders to understand growth drivers, emerging opportunities, and potential challenges within the Lupus Nephritis landscape.

DelveInsight’s estimates indicate that the US held the largest share of the Lupus Nephritis market in 2024. Within the EU4 and the UK, Spain accounted for the highest Lupus Nephritis drug market share, followed by the UK, whereas France recorded the lowest share in 2024. In Japan, the Lupus Nephritis market was valued at approximately USD 49 million in 2024 and is projected to grow over the forecast period from 2025 to 2034.

The epidemiology section presents data and insights on Lupus Nephritis across the US, EU4 (Germany, France, Italy, and Spain), the UK, and Japan. In 2024, the number of diagnosed prevalent cases in the US was approximately 218,000, with expectations of growth throughout the forecast period.

In 2024, the EU4 and the UK had nearly 130,000 diagnosed prevalent cases of Lupus Nephritis. The US represented the largest share of the Lupus Nephritis population, accounting for about 60% of the 7MM in 2024. Within the EU4 and the UK, Spain recorded the highest number of diagnosed cases, followed by the UK, while France had the fewest cases. In the US, the age distribution of diagnosed cases in 2024 showed approximately 7% in individuals under 18 years and around 93% in those aged 18 years and older.

In 2024, Class IV was the most common form of Lupus Nephritis in Japan, with approximately 18,000 diagnosed cases, indicating a persistently high disease burden. Class III was the second most prevalent subtype, with around 6,800 cases reported.

DelveInsight’s report “Lupus Nephritis Market Insights, Epidemiology, and Market Forecast-2034,” provides a comprehensive analysis of the Lupus Nephritis landscape. The report delivers detailed insights into the disease, including historical and projected epidemiology, helping stakeholders understand the prevalence, incidence, and patient demographics across key regions.

To Know in detail about the Lupus Nephritis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Lupus Nephritis Market Forecast

Some of the key facts of the Lupus Nephritis Market Report:  

• Key Lupus Nephritis Companies: Aurinia Pharmaceuticals, Otsuka Pharmaceuticals, GlaxoSmithKline, Roche, Novartis, Inflection Biosciences, Roche, Equillium, BeiGene, Janssen Research & Development, Horizon Therapeutics, Novartis, Roche, AstraZeneca, Novartis, Alexion Pharmaceuticals, AstraZeneca, Equillium, and others
• Key Lupus Nephritis Therapies: LUPKYNIS (voclosporin), BENLYSTA (belimumab), GAZYVA/GAZYVARO (obinutuzumab), Ianalumab (VAY736), IBL-101, RG 6107, Itolizumab, Zanubrutinib, Guselkumab, Daxdilimab, Secukinumab, Obinutuzumab, GAZYVA, Saphnelo (Anifrolumab), Iscalimab, Cosentyx, Ravulizumab, Anifrolumab, Itolizumab, and others
• The Lupus Nephritis market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Lupus Nephritis pipeline products will significantly revolutionize the Lupus Nephritis market dynamics.

Lupus Nephritis Overview

Lupus nephritis is a serious complication of systemic lupus erythematosus (SLE), an autoimmune disease. It specifically refers to inflammation of the kidneys caused by the immune system mistakenly attacking the kidney tissues. 

Get a Free sample for the Lupus Nephritis Market Report:

https://www.delveinsight.com/report-store/lupus-nephritis-market

Lupus Nephritis Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Lupus Nephritis Epidemiology Segmentation:

The Lupus Nephritis market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

• Total Prevalence of Lupus Nephritis
• Prevalent Cases of Lupus Nephritis by severity
• Gender-specific Prevalence of Lupus Nephritis
• Diagnosed Cases of Episodic and Chronic Lupus Nephritis 

Download the report to understand which factors are driving Lupus Nephritis epidemiology trends @ Lupus Nephritis Epidemiological Insights

Recent Developments In The Lupus Nephritis Treatment Landscape:

• In March 2025, Roche (SIX: RO, ROG; OTCQX: RHHBY) has announced that the U.S. Food and Drug Administration (FDA) has accepted its supplemental Biologics License Application (sBLA) for Gazyva®/Gazyvaro® (obinutuzumab) for the treatment of lupus nephritis. This acceptance is supported by positive findings from the Phase III REGENCY trial, which demonstrated enhanced complete renal response (CRR) when Gazyva/Gazyvaro was added to standard therapy, compared to standard treatment alone. The FDA is expected to deliver a decision on the application by October 2025.
• In February 2025, the FDA approved Allogene Therapeutics' investigational new drug (IND) application for ALLO-329, an allogeneic CAR-T cell therapy. The Phase 1 RESOLUTION trial is expected to commence in mid-2025, targeting autoimmune diseases such as systemic lupus erythematosus (SLE), lupus nephritis, idiopathic inflammatory myopathies, and systemic sclerosis.
• In November 2024, Adicet Bio reported that the initial patient with lupus nephritis (LN) has received a dose in its Phase I clinical trial assessing ADI-001 for autoimmune disorders.
• In November 2024, Kyverna Therapeutics revealed plans to share updated clinical data from lupus nephritis (LN) patients treated with KYV-101 in its ongoing KYSA-1 and KYSA-3 Phase I/II trials, as well as through named patient treatments.

Lupus Nephritis Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Lupus Nephritis market or expected to get launched during the study period. The analysis covers Lupus Nephritis market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Lupus Nephritis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Lupus Nephritis Therapies and Key Companies

• LUPKYNIS (voclosporin): Aurinia Pharmaceuticals/Otsuka Pharmaceuticals
• BENLYSTA (belimumab): GlaxoSmithKline
• GAZYVA/GAZYVARO (obinutuzumab): Roche
• Ianalumab (VAY736): Novartis
• Secukinumab: Novartis
• Obinutuzumab: Roche
• GAZYVA: Roche
• Saphnelo (Anifrolumab): AstraZeneca
• Iscalimab: Novartis
• IBL-101: Inflection Biosciences
• RG 6107: Roche
• Itolizumab: Equillium
• Zanubrutinib: BeiGene
• Guselkumab: Janssen Research & Development
• Daxdilimab: Horizon Therapeutics
• Cosentyx: Novartis
• Ravulizumab: Alexion Pharmaceuticals
• Anifrolumab: AstraZeneca

To know more about Lupus Nephritis treatment, visit @ Lupus Nephritis Medications

Lupus Nephritis Market Drivers

• Rising prevalence of lupus and autoimmune disorders leading to increased cases of lupus nephritis.
• Advancements in diagnostic tools allowing earlier and more accurate detection.
• Introduction of novel therapies and biologics improving patient outcomes.
• Growing awareness among physicians and patients about lupus nephritis management.
• Expansion of healthcare infrastructure and access to treatment in developed and emerging markets.
• Increased R&D investment by pharmaceutical companies driving pipeline innovations.

Lupus Nephritis Market Barriers

• High treatment costs limiting accessibility, especially in emerging markets.
• Limited availability of specialized therapies in certain regions.
• Side effects and long-term complications associated with existing treatment options.
• Delayed diagnosis or misdiagnosis due to complex symptoms.
• Regulatory challenges and slow approval processes for new drugs.
• Patient non-compliance with long-term treatment regimens.

Scope of the Lupus Nephritis Market Report

• Study Period: 2020–2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Lupus Nephritis Companies: Aurinia Pharmaceuticals, Otsuka Pharmaceuticals, GlaxoSmithKline, Roche, Novartis, Inflection Biosciences, Roche, Equillium, BeiGene, Janssen Research & Development, Horizon Therapeutics, Novartis, Roche, AstraZeneca, Novartis, Alexion Pharmaceuticals, AstraZeneca, Equillium, and others
• Key Lupus Nephritis Therapies: LUPKYNIS (voclosporin), BENLYSTA (belimumab), GAZYVA/GAZYVARO (obinutuzumab), Ianalumab (VAY736), IBL-101, RG 6107, Itolizumab, Zanubrutinib, Guselkumab, Daxdilimab, Secukinumab, Obinutuzumab, GAZYVA, Saphnelo (Anifrolumab), Iscalimab, Cosentyx, Ravulizumab, Anifrolumab, Itolizumab, and others
• Lupus Nephritis Therapeutic Assessment: Lupus Nephritis current marketed and Lupus Nephritis emerging therapies
• Lupus Nephritis Market Dynamics: Lupus Nephritis market drivers and Lupus Nephritis market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
• Lupus Nephritis Unmet Needs, KOL’s views, Analyst’s views, Lupus Nephritis Market Access and Reimbursement 

Discover more about therapies set to grab major Lupus Nephritis market share @ Lupus Nephritis Clinical Trials and Therapeutic Assessment